Roche acquires Trophos

19-Jan-2015 - Roche announced that it has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. Trophos’s proprietary screening platform generated olesoxime (TRO19622), which is being developed for SMA – a rare and debilitating genetic neuromuscular disease that is most ...

Trophos announces positive interim review in pivotal study of olesoxime in Spinal Muscular Atrophy

04-Mar-2013 - Trophos SA announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).The independent Data Monitoring Committee (DMC) has reviewed the treatment effect at one year on the primary outcome ...

Trophos announces conclusion of MitoTarget Consortium, achieving advanced understanding of neurodegenerative diseases

15-Aug-2012 - Trophos SA announced the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC.The results obtained in this project included additional confirmation that mitochondrial dysfunction plays an important role in neuron ...

Trophos appoints Christine Placet as chief executive officer

19-Jun-2012 - Trophos SA announced the appointment of Christine Placet as chief executive officer, effective immediately.Christine was previously CFO of Trophos since 2004. Christine becomes CEO under a previously defined internal succession plan designed to provide continuity for Trophos. Trophos is financed ...

Trophos announces results of phase III study of olesoxime in Amyotrophic Lateral Sclerosis

15-Dec-2011 - Trophos SA announced the results from the phase III study of Trophos’ lead compound, olesoxime, in 512 patients with ALS. Olesoxime did not demonstrate a significant increase in survival versus placebo in patients receiving riluzole (Rilutek(R)). A trend was seen on patients’ function as measured ...

Trophos announces final patient completion of pivotal phase three efficacy study of olesoxime in Amyotrophic Lateral Sclerosis

27-Sep-2011 - Trophos SA announced that the last patient has now completed the major pivotal phase three efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (ALS).Over 500 patients were enrolled in the study and the last patient completed the prescribed study protocol procedures on 15th September. ...

Trophos awarded key US patent covering use of novel cardioprotective compound, TRO40303

Patent protection granted until 2028

26-Aug-2011 - Trophos SA announced that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that ...

Trophos successfully completes phase 1 study for novel cardioprotective compound, TRO40303

Phase 2 Proof-of-Concept study in acute myocardial infarction planned for second half 2011 with MitoCare EU consortium

28-Feb-2011 - Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the successful completion of its phase 1 dose escalation study of TRO40303, a novel ...

Trophos to lead new MitoCare consortium awarded EUR 6 million by EU for POC study of novel cardioprotective compound, TRO40303

Program of translational research to study innovative approaches to reducing cardiac ischemia-reperfusion injury

17-Dec-2010 - Trophos SA announced a European Union award of EUR 6 million to support MitoCare, a 2.5 year international, translational medicine project. MitoCare, which will begin in January 2011, will be conducted by a 16 partner consortium and led by Trophos. MitoCare forms part of the Seventh Framework ...

Trophos and MS-Repair partners present promising data on novel approach in multiple sclerosis

25-Nov-2010 - Trophos SA announced that Trophos and partners in the MS-Repair consortium delivered an oral presentation detailing Trophos’ novel approach in multiple sclerosis (MS) at the recent Society for Neuroscience (SfN) Meeting. The data presented demonstrate that olesoxime, Trophos’ lead compound, is a ...